News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Hatem Soliman, MD

Articles by Hatem Soliman, MD

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

ByKatheryn Moreira,Kathryn Hudson,Wambui Gathirua-Mwangi,Zhanglin Lin Cui,Madeline Richey,Brenda Grimes,Jingru Wang,Astra Liepa,Erich Brechtelsbauer,Raisa Volodarsky,Hatem Soliman, MD

May 24th 2025

20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer

ByErika P. Hamilton, MD,Lajos Pusztai, MD, DPhil,Hatem Soliman, MD,Sara A. Hurvitz, MD,Krzysztof J. Grzegorzewski,Nassir Habboubi,Priya Marreddy,Tarek Sahmoud, MD,Nuhad Ibrahim, MD

April 28th 2023

Propelling Immunotherapy Combinations Into the Clinic

ByNishan Tchekmedyian, MD,Jhanelle E. Gray, MD,Benjamin C. Creelan, MD,Alberto A. Chiappori, MD,Amer A. Beg, PhD,Hatem Soliman, MD,Bradford A. Perez, MD,Scott J. Antonia, MD, PhD

December 15th 2015

This review summarizes promising new targets and immunotherapy combination strategies currently under clinical development.

Latest Updated Articles

Propelling Immunotherapy Combinations Into the Clinic
December 15th 2015

Trending on CancerNetwork

MYTHIC Trial Demonstrates Efficacy in Platinum-Resistant Ovarian Cancer

Selecting Among Preferred 1L Regimens — A Discussion

What is the Future of TIL Therapy in Metastatic Melanoma?

Clinical Context & MARIPOSA Efficacy in 1L EGFRm NSCLC

Novel HP1K Inhibitor Shows Favorable Responses in ccRCC, Solid Tumors